-
Featured
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
Noopur Raje, MD, of the Massachusetts General Hospital Cancer Center, and colleagues determined in a phase 1 trial that idecabtagene vicleucel had promising antitumor activity in a heavily pretreated population of patients with multiple myeloma, and most nonhematologic toxic effects were grade 1 or 2.
-
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution
David M. Langenau, PhD, Marcela V. Maus, MD, PhD, and colleagues created a new line of transparent zebrafish that allow single-cell imaging of tumor cell killing during immunotherapy with CAR T-cells, bispecific T-cell engagers and antibody–peptide epitope conjugates in a wide range of cancers.
-
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
Bob S. Carter, MD, PhD, is the chief of the Department of Neurosurgery at Massachusetts General Hospital. In this Q&A, Dr. Carter elaborates on intraoperative molecular diagnostics. Dr. Carter is also a 2021 Congress of Neurological Surgeons (CNS) honored guest.
-
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
Massachusetts General Hospital researchers observed low rates of acute kidney injury (AKI) after tisagenlecleucel therapy but detected the first case of AKI in a patient with macrophage activation syndrome/hemophagocytic lymphohistiocytosis triggered by the therapy.
-
Phase 1 Trial Supports Safety and Efficacy of Novel CAR-T Therapy for Large B-cell Lymphomas
Lisocabtagene maraleucel, an investigational CAR T-cell product, was linked to low incidence of cytokine release syndrome and neurological events in a phase 1 seamless design pivotal trial and often led to rapid and durable remission among patients with high-risk relapsed/refractory large B-cell lymphoma.
-
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma
Central nervous system involvement does not appear to be a risk factor for severe neurotoxicity with CD19-directed CAR T-cell therapy.
CAR T-cell Therapy Contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD -
Daniel B. Rubin, MD, PhD
Neurologist
Recent Article
New Tool Identifies Risk of Neurotoxicity After CAR T-cell Therapy -
Jeremy Slade Abramson, MD
Director, Jon and JoAnn Hagler Center for Lymphoma, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Phase 1 Trial Supports Safety and Efficacy of Novel CAR-T Therapy for Large B-cell Lymphomas -
Meghan E. Sise, MD
Nephrologist, Massachusetts General Hospital, Associate Professor of Medicine
Recent Article
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy -
Noopur S. Raje, MD
Director of the Multiple Myeloma Center, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Recent Article
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma -
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors -
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Immunotherapies to Treat Glioblastoma